Aurora Financial JournalCinclus Pharma Holding AB (CINPHA.ST)
Nasdaq Stockholm · Financial statements, TTM figures and earnings dates
Annual financial statements are available for fiscal years 2023 to 2024, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| SEK | FY2024 2024-12-31 | FY2023 2023-12-31 |
|---|---|---|
| Income statement | ||
| Operating income | −SEK 169.6M | −SEK 201.0M |
| Net income | −SEK 168.0M | −SEK 215.1M |
| Diluted EPS | −SEK 4.54 | −SEK 8.20 |
| Cash flow | ||
| Operating cash flow | −SEK 178.4M | −SEK 209.2M |
| Balance sheet | ||
| Cash and equivalents | SEK 566.7M | SEK 88.0M |
| Total assets | SEK 601.0M | SEK 94.4M |
| Total liabilities | SEK 45.7M | SEK 171.2M |
| Shareholders' equity | SEK 555.3M | −SEK 76.8M |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full CINPHA.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open CINPHA.ST financials →